Eli Lilly's New Weight-Loss Pill Underperforms in Initial Sales, Pressing Down Stock
Eli Lilly's new FDA-approved weight-loss pill, Foundayo, saw slower-than-expected initial prescriptions, leading to a 4% drop in its stock price on Friday. Foundayo's first week of prescriptions totaled 3,707, significantly lower than Novo Nordisk's Wegovy, which had 18,410 prescriptions in its second week. The underperformance raised doubts about the drug's market potential and dampened investor sentiment.
Topics: FDA approval market reaction pharmaceuticals stock performance weight-loss drug